SEC Info - Elevance Health, Inc. - ‘10-Q’ for 3/31/21

SEC Info℠

Home

Help

Please Sign In

Elevance Health, Inc. – ‘10-Q’ for 3/31/21 – ‘EX-101.SCH’

On: Wednesday, 4/21/21, at 12:55pm ET · For: 3/31/21 · Accession #: 1156039-21-41 · File #: 1-16751

  As Of               Filer                 Filing    For·On·As Docs:Size

 4/21/21  Anthem, Inc.                      10-Q        3/31/21   97:12M

Quarterly Report — Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.35M 
 2: EX-10.2(M)  Material Contract                                   HTML     73K 
 3: EX-10.2(N)  Material Contract                                   HTML     76K 
 4: EX-10.2(O)  Material Contract                                   HTML     77K 
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     31K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     31K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     28K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     28K 
15: R1          Document And Entity Information Document            HTML     80K 
16: R2          Consolidated Balance Sheets                         HTML    141K 
17: R3          Consolidated Balance Sheets (Parenthetical)         HTML     52K 
18: R4          Consolidated Statements Of Income                   HTML    108K 
19: R5          Consolidated Statements of Comprehensive Income     HTML     64K 
20: R6          Consolidated Statements Of Cash Flows               HTML    124K 
21: R7          Consolidated Statements Of Shareholders' Equity     HTML    117K 
22: R8          Organization                                        HTML     32K 
23: R9          Basis Of Presentation and Significant Accounting    HTML     51K 
                Policies                                                         
24: R10         Business Acquisitions                               HTML     34K 
25: R11         Business Optimization Initiatives                   HTML     43K 
26: R12         Investments                                         HTML    244K 
27: R13         Derivative Financial Instruments                    HTML     31K 
28: R14         Fair Value                                          HTML    233K 
29: R15         Income Taxes                                        HTML     31K 
30: R16         Medical Claims Payable                              HTML    116K 
31: R17         Debt                                                HTML     40K 
32: R18         Commitments And Contingencies                       HTML     61K 
33: R19         Capital Stock                                       HTML     79K 
34: R20         Accumulated Other Comprehensive Loss                HTML     74K 
35: R21         Earnings Per Share                                  HTML     36K 
36: R22         Segment Information                                 HTML    105K 
37: R23         Leases                                              HTML     55K 
38: R24         Basis of Presentation and Significant Accounting    HTML     65K 
                Policies (Policies)                                              
39: R25         Business Optimization Initiatives (Tables)          HTML     43K 
40: R26         Investments (Tables)                                HTML    249K 
41: R27         Fair Value (Tables)                                 HTML    205K 
42: R28         Medical Claims Payable (Tables)                     HTML    121K 
43: R29         Debt (Tables)                                       HTML     33K 
44: R30         Capital Stock (Tables)                              HTML     86K 
45: R31         Accumulated Other Comprehensive Income (Tables)     HTML     76K 
46: R32         Earnings Per Share (Tables)                         HTML     35K 
47: R33         Segment Information (Tables)                        HTML    105K 
48: R34         Leases (Tables)                                     HTML     57K 
49: R35         Organization (Details)                              HTML     32K 
50: R36         Basis of Presentation and Signficant Accounting     HTML     39K 
                Policies Basis of Presentation and Significant                   
                Acconting Policies (Details)                                     
51: R37         Business Acquisitions Business Acquisition (Assets  HTML     53K 
                Liabilities Acquired) (Details)                                  
52: R38         Business Optimization Initiatives (Employee         HTML     44K 
                Termination Costs) (Details)                                     
53: R39         Investments (Current And Long-Term Fixed Maturity   HTML     92K 
                Securities, Available-For-Sale) (Details)                        
54: R40         Investments (Aggregate Fair Value And Gross         HTML     76K 
                Unrealized Loss Of Fixed Maturity Securities In An               
                Unrealized Loss Position) (Details)                              
55: R41         Investments (Allowance For Credit Loss              HTML     42K 
                Rollforward) (Details)                                           
56: R42         Investments (Amortized Cost And Fair Value Of       HTML     59K 
                Fixed Maturity Securities, By Contractual                        
                Maturity) (Details)                                              
57: R43         Investments (Current and Long-term Equity           HTML     37K 
                Securities) (Details)                                            
58: R44         Investments (Net Realized Investment Gains/Losses)  HTML     50K 
                (Details)                                                        
59: R45         Investments (Gains and Losses Recognized on Equity  HTML     35K 
                Securities) (Details)                                            
60: R46         Investments (Securities Lending Programs)           HTML     42K 
                (Details)                                                        
61: R47         Investments (Narrative) (Details)                   HTML     36K 
62: R48         Derivative Financial Instruments (Financial         HTML     34K 
                Statement Narrative) (Details)                                   
63: R49         Fair Value (Fair Value Measurements By Level For    HTML    147K 
                Assets Measured At Fair Value On A Recurring                     
                Basis) (Details)                                                 
64: R50         Fair Value (Reconciliation Of The Beginning And     HTML     68K 
                Ending Balances Of Assets Measured At Fair Value                 
                On A Recurring Basis Using Level III Inputs)                     
                (Details)                                                        
65: R51         Fair Value (Carrying And Estimated Fair Values by   HTML     51K 
                Level Of Financial Instruments Not Recorded At                   
                Fair Value On Consolidated Balance Sheet)                        
                (Details)                                                        
66: R52         Income Taxes (Narrative) (Details)                  HTML     38K 
67: R53         Medical Claims Payable (Reconciliation Of The       HTML     75K 
                Beginning And Ending Balances For Medical Claims                 
                Payable By Segment) (Details)                                    
68: R54         Medical Claims Payable (Reconciliation Of Net       HTML     41K 
                Incurred Medical Claims To Benefit Expense)                      
                (Details)                                                        
69: R55         Medical Claims Payable Medical Claims Payable       HTML     50K 
                (Reconciliation of the Claims Development to the                 
                Claims Liability) (Details)                                      
70: R56         Medical Claims Payable (Narrative) (Details)        HTML     46K 
71: R57         Debt (Convertible Debenture Details) (Details)      HTML     44K 
72: R58         Debt (Narrative) (Details)                          HTML     87K 
73: R59         Commitments And Contingencies (Details)             HTML     53K 
74: R60         Capital Stock (Summary of Cash Dividend Activity)   HTML     36K 
                (Details)                                                        
75: R61         Capital Stock (Summary of Share Repurchases)        HTML     37K 
                (Details)                                                        
76: R62         Capital Stock (Summary of Stock Option Activity)    HTML     64K 
                (Details)                                                        
77: R63         Capital Stock (Nonvested Restricted Stock Activity  HTML     50K 
                Including Restricted Stock Units) (Details)                      
78: R64         Capital Stock (Fair Values of Options Granted       HTML     37K 
                During The Period Estimated Using Weighted-Average               
                Assumptions) (Details)                                           
79: R65         Capital Stock (Schedule Of Weighted-Average Fair    HTML     31K 
                Values Determined For The Periods) (Details)                     
80: R66         Capital Stock (Narrative) (Details)                 HTML     46K 
81: R67         Accumulated Other Comprehensive Loss                HTML     86K 
                (Reconciliation Of The Components Of Accumulated                 
                Other Comprehensive Income) (Details)                            
82: R68         Accumulated Other Comprehensive Income (Other       HTML     57K 
                Comprehensive Income (Loss) Reclassification                     
                Adjustments) (Details)                                           
83: R69         Accumulated Other Comprehensive Income (Loss)       HTML     53K 
                Accumulated Other Comprehensive Income                           
                Reclassification Adjustments (Details)                           
84: R70         Earnings Per Share (Denominator For Basic And       HTML     34K 
                Diluted Earnings Per Share) (Details)                            
85: R71         Earnings Per Share (Narrative) (Details)            HTML     33K 
86: R72         Segment Information (Financial Data By Reportable   HTML     59K 
                Segment) (Details)                                               
87: R73         Segment Information Segment Information (Major      HTML     56K 
                Product Revenues for Each Reportable Segment)                    
                (Details)                                                        
88: R74         Segment Information (Reconciliation Of Reportable   HTML     38K 
                Segments Operating Revenues To Total Revenues                    
                Reported In The Consolidated Statements Of Income)               
                (Details)                                                        
89: R75         Segment Information (Reconciliation Of Reportable   HTML     46K 
                Segments Operating Gain To Income Before Income                  
                Tax Expense Included In The Consolidated                         
                Statements Of Income) (Details)                                  
90: R76         Segment Information Segment Information             HTML     29K 
                (Narrative) (Details)                                            
91: R77         Leases (Lease and Other Information) (Details)      HTML     50K 
92: R78         Leases (Reconciliation of Future Lease Payments to  HTML     46K 
                Total Lease Liabilities) (Details)                               
93: R79         Leases (Narrative) (Details)                        HTML     45K 
95: XML         IDEA XML File -- Filing Summary                      XML    182K 
14: XML         XBRL Instance -- antm-20210331_htm                   XML   3.57M 
94: EXCEL       IDEA Workbook of Financial Reports                  XLSX    131K 
10: EX-101.CAL  XBRL Calculations -- antm-20210331_cal               XML    271K 
11: EX-101.DEF  XBRL Definitions -- antm-20210331_def                XML    908K 
12: EX-101.LAB  XBRL Labels -- antm-20210331_lab                     XML   2.18M 
13: EX-101.PRE  XBRL Presentations -- antm-20210331_pre              XML   1.32M 
 9: EX-101.SCH  XBRL Schema -- antm-20210331                         XSD    201K 
96: JSON        XBRL Instance as JSON Data -- MetaLinks              512±   779K 
97: ZIP         XBRL Zipped Folder -- 0001156039-21-000041-xbrl      Zip    442K

‘EX-101.SCH’ — XBRL Schema — antm-20210331

This Exhibit is an XBRL XML File.

<?xml version="1.0" encoding="windows-1252"?>

<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:antm="http://www.antheminc.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.antheminc.com/20210331">

<xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>

<xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>

<xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>

<xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>

<xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>

<xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>

<xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>

<xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>

<xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>

<xs:annotation>

<xs:appinfo>

<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="antm-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="antm-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="antm-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="antm-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>

<link:roleType id="DocumentAndEntityInformationDocument" roleURI="http://www.antheminc.com/role/DocumentAndEntityInformationDocument">

<link:definition> 0001001 - Document - Document And Entity Information Document </link:definition>

<link:usedOn> link:presentationLink </link:usedOn>